Decibel Therapeutics Announces Approval of Clinical Trial Application by the Spanish Agency of Medicines and Medical Devices (AEMPS) to Initiate Clinical Development of Lead Gene Therapy Candidate DB-OTO

CTA authorization provides approval for the Company to expand its planned CHORD™ Phase 1/2 clinical trial of DB-OTO to patients in Spain aged two years and youngerBOSTON, May 12, 2023 --... | May 12, 2023

Related Keywords

Boston ,Massachusetts ,United States ,Spain ,Spanish ,Julie Seidel ,Chris Railey ,Laurence Reid ,Stern Ir Inc ,Regeneron Pharmaceuticals Inc ,Healthcare Products Regulatory Agency ,European Medicines Agency ,Drug Administration ,Exchange Commission ,Twitter ,Spanish Agency Of Medicines ,Committee On Orphan Medicinal Products ,Clinical Trial Application ,Spanish Agency ,Medical Devices ,Regeneron Pharmaceuticals ,Investigational New Drug ,Chief Executive Officer ,Orphan Drug ,Rare Pediatric Disease ,European Orphan Drug ,Orphan Medicinal Products ,Decibel Therapeutics ,Private Securities Litigation Reform Act ,Annual Report ,Nc Stock Exchange ,News ,Information ,Press Release ,Data ,Authorization ,Rovides ,Approval ,Or ,The ,Company ,O ,Xpand ,Its ,Planned ,Hase ,Linical ,Trial ,F ,Patients ,N ,Ged ,Two ,Tears ,End ,Bay ,023 Dbtx Us24343r1068 ,